Mitotane

• UNSPSC Description:

  Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions[1][2][3][4].

• Target Antigen:

  Apoptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mitotane.html

• Smiles:

  ClC1=CC=C(C(C2=CC=CC=C2Cl)C(Cl)Cl)C=C1

• Molecular Weight:

  320.04

• References & Citations:

  [1]Takeshita A, Igarashi-Migitaka J, Koibuchi N, Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol. 2013 Feb 15;216(3):297-305.|[2]Doghman M, et al. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. Mol Cell Endocrinol. 2013 Dec 5;381(1-2):66-9.|[3]Zatelli MC, et al. Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology. 2010 Jun;151(6):2453-61.|[4]Warde KM, et al. Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma. Endocrinology. 2022 Sep 1;163(9):bqac102.

• Shipping Conditions:

  Room Temperature

• CAS Number:

  53-19-0